Amax Photo Tilray (NASDAQ:TLRY) reported positive results from a study of an oral cannabis extract
David Trood U.S.-listed cannabis stocks slipped in premarket trading on Wednesday after a costly campaign
Summary: I have been negative on Tilray Brands for quite some time and remain so.
Summary: Tilray’s Q1 revenue missed estimates by $21 million, showing 13% year-over-year growth driven by
strelov The upcoming U.S. presidential elections will likely bring about positive changes for the cannabis
Tilray press release (NASDAQ:TLRY): Q1 Non-GAAP EPS of -$0.01 beats by $0.02. Revenue of $200.04M
Tilray (NASDAQ:TLRY) is scheduled to announce Q1 earnings results on Thursday, October 10th, before market
Summary: Tilray is set to report its Q1 FY 2025 earnings on October 10th. I